Wednesday February 10, 2016 0 comments
BOULDER -- SomaLogic, Inc., announced Matthew Norkunas, M.D., has joined the company as chief financial officer.
“We are excited that Matt has agreed to join us during this critical growth period for SomaLogic,” said Byron Hewett, CEO. “His unique combination of experience and knowledge matches up well with our needs as we continue our transition from a start-up company to a successful business organization.”
“I look forward to working with the amazing SomaLogic team to realize the full potential of their R&D work over the past 15 years,” said Dr. Norkunas. “Their powerful technology should transform many areas of the life sciences and healthcare, and I am excited to help lead those efforts.“
Prior to SomaLogic, Norkunas was a senior research analyst at Marsico Capital Management in Denver, focused on biotech, pharma, life sciences, and diagnostics companies. While at Marsico, he valuated companies at both the private and public level, spearheading firm participation in a number of capital market transactions for companies in the space, including secondary equity, IPO, crossover and debt financings.
In addition to his experience in the venture capital industry, Norkunas is a board-certified anesthesiologist. During his medical career, he also served three years as VP of New Business Development for AABP, a private physician group in New York City that grew rapidly under his business development leadership, including the foundation of a new regional anesthesia program.
Norkunas actively participated in various clinical trials during those years, authored scientific publications and presentations, and developed two patents (pending) for medical devices. He received his anesthesia training at Mount Sinai in New York, and earned his M.D. from the University of Maryland Medical School, his M.B.A. from Columbia University, and his B.A. in Biology from St. Mary’s College of Maryland.